NEW YORK, May 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies") (NASDAQ:ITCI) between August 12, 2014 and April 28, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-sb/intra-cellular-therapies-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
If you suffered a loss in Intra-Cellular Therapies you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Meta Expands AI Training With Employee Activity Tracking Tools
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 



